Ticagrelor antidote restores platelet function in phase 3 study
ACC.25 – In the phase 3 REVERSE-IT trial, the investigational monoclonal antibody bentracimab effectively and safely reversed the antiplatelet effect of ticagrelor in patients undergoing urgent surgery or with major bleeding.
